406
Participants
Start Date
May 9, 2011
Primary Completion Date
June 3, 2013
Study Completion Date
March 30, 2015
VEGF Trap-Eye (BAY86-5321)
Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
VEGF Trap-Eye (BAY86-5321)
Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
Macular Laser Photocoagulation (Control)
Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
Budapest
Vienna
Budapest
Budapest
Sydney
Westmead
Parramatta
Glostrup Municipality
East Melbourne
Linz
Linz
Debrecen
Nedlands
Århus C
Barcelona
Veszprém
Berlin
Santiago de Compostela
IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, Milan
Milan
Kiel
Pamplona
Oviedo
Bordeaux
Padua
Göttingen
Nantes
Valencia
Cologne
Aachen
Bonn
Mainz
Ancona
Darmstadt
Klinikum der Stadt Ludwigshafen am Rhein gGmbH, Ludwigshafen am Rhein
Lyon
Heidelberg
Tübingen
Hopital Lariboisiere, Paris
Paris
Freiburg im Breisgau
München
Créteil
Faculty Hospital Hradec Kralove, Hradec Králové
Olomouc
Ostrava
Prague
Zalaegerszeg
Rome
Rome
Nagoya
Nagoya
Asahikwa
Sapporo
Kawasaki
Sendai
Matsumoto
Hirakata
Chiyoda-ku
Itabashi-ku
Mitaka
Shinjuku-ku
Akita
Chiba
Fukuoka
Nagasaki
Osaka
Wakayama
Bytom
Wroclaw
Wroclaw
San Cugat Del Vallès
Alicante
Lead Sponsor
Regeneron Pharmaceuticals
INDUSTRY
Bayer
INDUSTRY